ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0054

Temporal Trends in Mortality and Hospitalization Related to SARS-CoV-2 in Dialysis Patients in Québec (Canada)

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Nadeau-Fredette, Annie-Claire, Hopital Maisonneuve-Rosemont Centre de Recherche, Montreal, Quebec, Canada
  • Beaubien-Souligny, William, Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
  • Mac-Way, Fabrice, CHU de Quebec-Universite Laval, Quebec, Quebec, Canada
  • Goupil, Remi, Hopital du Sacre-Coeur de Montreal Centre de Recherche, Montreal, Quebec, Canada
  • Blum, Daniel, McGill University Health Centre, Montreal, Quebec, Canada
  • Suri, Rita, McGill University Health Centre, Montreal, Quebec, Canada

Group or Team Name

  • For the Quebec Renal Network Study Group

In Canada, Quebec province was the most severely hit region during the first year of the SARS-CoV-2 pandemic. We aimed to compare characteristics and outcomes of dialysis patients during the first and second SARS-CoV-2 transmission surges in this province.


The QRN-COVID-HD study included adult dialysis patients from 13 units in Quebec, with SARS-CoV-2 PCR tests performed between Mar-Sept 2020 (1st wave) and Oct 2020-Feb 2021 (2nd wave). Crude and stratified rates of mortality, hospitalization and intensive care unit (ICU) admission within 90-day of SARS-CoV-2 positivity were calculated with mixed effect Poisson regressions. Adjusted predictors of 90-day outcomes were evaluated using mixed effect logistic regressions and negative binomial regressions (as appropriate).


Over this 12-month period, 431 patients were infected with SARS-CoV-2 (211 1st wave; 220 2nd wave). Most characteristics (including age) were similar in the two waves although 2nd wave patients were less frequently living in long-term care facilities and had more diabetic nephropathy. Overall, 214 (50%) patients were hospitalized at least once and 214 (26%) died within 90-day of SARS-CoV-2 positivity, with 78% of hospitalizations and 84% of deaths directly attributed to SARS-CoV-2. Mortality and hospitalization rates were lower for 2nd compared to 1st wave patients. Figure In contrast, ICU admissions were similar in both waves (0.14, 95% CI 0.10-0.19 [1st] vs. 0.13, 95% CI 0.09-0.18 [2nd] per 100 pt-yrs). When adjusted for case-mixed differences, the 2nd wave remained associated with lower risk of mortality (OR 0.55, 95% CI 0.32-0.95), hospitalization (OR 0.45, 95%CI 0.28-0.71) and days in hospital (IRR 0.49, 95% CI 0.46-0.53), but similar risk of ICU (OR 0.73; 95% CI 0.39-1.37).


Dialysis patients with SARS-CoV-2 infections had more favorable clinical outcomes during the 2nd wave, which is consistent with observations in the general population and may be related to improved clinical care.


  • Government Support – Non-U.S.